Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + Octreotide LAR first-line treatment for G1-G2 gastroenteropancreatic neuroendocrine tumors
ChiCTR2100048509Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib and octreotide LAR in Gastroenteropancreatic Carcinoid Tumor, sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: 6-month progression-free survival. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
surufatiniboctreotide LAR
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on ChiCTR2100048509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048509.